Merck MRK continues to face challenges with its second-largest product, Gardasil, which is a vaccine approved to prevent certain cancers caused by the human papillomavirus. While the vaccine’s sales ...

Opportunities in the Abrysvo market are driven by unmet RSV vaccine needs, aging populations, rising RSV cases, and expanded adult immunization programs. Growth is supported by enhanced vaccine access ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. | Gilead penned a potential ...

Across China, people have shared a growing number of stories about sudden deaths in adults who seemed healthy. Many reports focus on ages 30 to 50.

During this latest round of earnings calls, marketing didn’t factor heavily in these discussions. Lilly did address sharply rising commercial costs which go in tandem with its massive revenue growth, ...

On Tuesday, BMS announced that FDA had accepted the New Drug Application for iberdomide, a first-in-class CELMoD agent for relapsed/refractory multiple myeloma. In a new, transformative approach meant ...

Parents and children from a detention center in Texas found themselves dropped at a border town shelter with few means to leave.

SK bioscience, which transfer its headquarters and research institute from Pangyo in Seongnam, Gyeonggi Province, to Songdo last month, plans to lease out office space. According to the industry on ...

Today, Zacks Equity Research discusses Eli Lilly LLY, Johnson & Johnson JNJ, Sanofi SNY and Bayer BAYRY. Industry: Large-C ...

Merck started 2026 on a high note. Read why MRK stock is still one of the best choices among Big Pharma players for long-term-oriented investors.

It has been about a month since the last earnings report for Pfizer (PFE). Shares have lost about 0.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the ...

If the recommendation is accepted by the European Commission, Moderna's mCombriax vaccine will be available for adults 50 and older throughout the European Union.